Pacira BioSciences (PCRX) Accounts Payables (2010 - 2026)

Pacira BioSciences' Accounts Payables history runs 17 years deep, the most recent figure standing at $14.0 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 39.53% year-over-year to $14.0 million; the TTM figure through Mar 2026 stood at $14.0 million (down 39.53% YoY), while the FY2025 annual figure was $15.2 million, down 20.82% from the prior year.
• Accounts Payables was $14.0 million for Q1 2026 at Pacira BioSciences, down from $15.2 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $30.1 million in Q2 2025 to a low of $9.0 million in Q1 2024.
• Historically, Accounts Payables has averaged $17.5 million across 5 years, with a median of $16.5 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables slumped 47.96% in 2024, then surged 157.98% in 2025.
• A 5-year view of Accounts Payables shows it stood at $15.2 million in 2022, then advanced by 3.14% to $15.7 million in 2023, then climbed by 21.88% to $19.1 million in 2024, then slipped by 20.82% to $15.2 million in 2025, then slipped by 7.51% to $14.0 million in 2026.
• The last three Accounts Payables figures came in at $14.0 million (Q1 2026), $15.2 million (Q4 2025), and $17.7 million (Q3 2025), per Business Quant data.